NCT04926259 is a EARLY_PHASE1 clinical trial of 18F-T807 in Neurodegenerative Disorders, sponsored by First Affiliated Hospital of Fujian Medical University.

Who is sponsoring NCT04926259?

NCT04926259 is sponsored by First Affiliated Hospital of Fujian Medical University.

What drugs are being tested in NCT04926259?

Interventions in NCT04926259: 18F-T807.

What condition does NCT04926259 study?

NCT04926259 studies Neurodegenerative Disorders.

Is NCT04926259 still recruiting?

NCT04926259 is currently status unknown. Last updated 26 November 2021.

Last reviewed 2021-11-26 · How we verify

NCT04926259

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tau PET Imaging With 18F-T807(AV1451) in Neurodegenerative Disorders

Status unknown EARLY_PHASE1 Last updated 26 November 2021

What this trial tests

EARLY_PHASE1 trial testing 18F-T807 in Neurodegenerative Disorders in 50 participants. Status unknown.

Timeline

1 November 2021

Primary endpoint
1 December 2024

1 December 2024

Quick facts

Lead sponsor	First Affiliated Hospital of Fujian Medical University
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	1 November 2021
Primary completion	1 December 2024
Estimated completion	1 December 2024
Sites	1 location across China

Drugs / interventions tested

18F-T807 — full drug profile →

Conditions studied

Neurodegenerative Disorders — all drugs for Neurodegenerative Disorders →

Sponsor

First Affiliated Hospital of Fujian Medical University

Who can join

Adults 18 to 90, any sex, with Neurodegenerative Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Alzheimer's disease, Parkinson's disease, and Huntington's disease are common neurodegenerative diseases. Tau is a microtubule-associated protein, and aggregated tau resulting from hyperphosphorylation is a pathological feature of a group of neurodegenerative diseases known as tauopathies. The 18F-T807 (AV1451) molecular probe is a novel molecularly targeted imaging agent that exhibits high affinity and good selectivity for tau.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Untangling the Role of Tau in Huntington's Disease Pathology.
Salem S, Cicchetti F. · · 2023 · cited 17× · PMID 36806513 · DOI 10.3233/jhd-220557

Verify or expand the search:

Other recruiting trials for Neurodegenerative Disorders

Currently open trials in the same condition.

NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT04684602 — Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions · Phase 1, PHASE2 · recruiting

Other First Affiliated Hospital of Fujian Medical University trials

Trials by the same sponsor.

NCT07513844 — Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease · NA · not yet recruiting
NCT07337772 — Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty · NA · recruiting
NCT07369401 — Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory · NA · not yet recruiting
NCT07378358 — Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study · recruiting
NCT07363382 — The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04926259 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Fujian Medical University
Last refreshed: 26 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04926259.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing